Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gastric Cancer

Gastric Cancer

46 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastric Cancer

191 trials tracked for Gastric Cancer: 32 in phase 3 or 4 and 19 with published results. The most-cited published study has 1127 citations.

191Trials tracked
32Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 2 Phase 3 30 Phase 2 121 Phase 1 15 Other / NA 23
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,127 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 689 cited
  3. Phase 3 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed · 511 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 501 cited
  5. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 490 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 388 cited
Show 44 more trials
  1. Phase 3 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Completed · 359 cited
  2. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 297 cited
  3. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 289 cited
  4. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 252 cited
  5. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 230 cited
  6. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 133 cited
  7. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 98 cited
  8. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 94 cited
  9. Phase 3 Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer Completed · 80 cited
  10. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  11. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 9 cited
  12. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  13. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  14. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  15. Phase 3 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Completed
  16. Phase 3 A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer Completed
  17. Phase 3 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed
  18. Phase 3 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Completed
  19. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  20. Phase 3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed
  21. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed
  22. Phase 3 A Safety and Efficacy Study in Patients With Gastric Cancer Completed
  23. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  24. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  25. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  26. Phase 3 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed
  27. Phase 2 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Completed
  28. Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Completed
  29. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  30. Phase 2 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Completed
  31. Phase 2 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment Completed
  32. Phase 2 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) Completed
  33. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  34. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  35. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer Completed
  36. Phase 2 Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Completed
  37. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  38. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  39. Phase 2 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  40. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  41. Phase 2 Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Completed
  42. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  43. Phase 2 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma Completed
  44. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed

Showing the 50 most-cited and recently-updated of 191 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Gastric Cancer: what the trials found

Pembrolizumab has demonstrated significant improvements in overall survival (OS) across multiple cohorts. In one study, OS was significantly improved in all participants (12.9 vs 11.5, p<0.0001), with even greater gains in patients with PD-L1 CPS ≥10 (15.7 vs 11.8, p<0.0001) 6. Another trial showed significant OS benefits for all participants (8.4 vs 5.6, p=0.0015), with specific benefits noted for patients with PD-L1 CPS ≥10 (12.0 vs 5.3, p=0.0008) 19. Additionally, pembrolizumab combined with XP/FP showed a statistically significant improvement in event-free survival (EFS) (44.4% vs 25.7%, p=0.01501) and a significantly higher pathological complete response (pathCR) rate (13.4% vs 2.0%, p<0.00001) 10.

Other immunotherapies and combinations have shown varying results. Nivolumab plus chemotherapy significantly improved both OS (14.39 vs 11.10, p<0.0001) and progression-free survival (PFS) (7.69 vs 6.05, p<0.0001) in patients with PD-L1 CPS ≥5 14. Tislelizumab showed significant improvements in OS for both PD-L1 positive participants (17.2 vs 12.6, p=0.0056) and the intent-to-treat population (15.0 vs 12.9, p=0.0011) 20. TAS-118 plus Oxaliplatin also demonstrated significant improvements in OS (16.0 vs 15.1, p=0.039), PFS (7.1 vs 6.4, p=0.0045), and time to treatment failure (6.1 vs 5.3, p=0.011) 18.

In contrast, some agents did not reach statistical significance in primary endpoints. TAS-102 showed a significant improvement in OS (5.7 vs 3.6, p=0.0003) 7, while Avelumab did not show significant improvements in OS (p=0.1779) 15 or in OS, PFS, or ORR (p>0.05) 8. Other trials, such as those involving 5-Fluorouracil 9, Olaparib 12, and Ramucirumab 13, provided data on response rates and survival but did not reach statistical significance for primary survival endpoints in the reported data.

recent": ["Perioperative treatment is currently being evaluated in a Phase 2 trial 1.", "Trastuzumab BS is under investigation in a Phase 1/2 trial 2."],

For the clinician treating this condition

  • Pembrolizumab is associated with significant improvements in OS and EFS, with notable benefits in patients with high PD-L1 expression [6, 10, 19].
  • Nivolumab plus chemotherapy and Tislelizumab have demonstrated statistically significant improvements in overall survival [14, 20].
  • TAS-118 plus Oxaliplatin showed significant improvements in OS, PFS, and time to treatment failure 18.
  • Avelumab did not demonstrate statistically significant improvements in OS or other primary endpoints in the reported trials [8, 15].

AI synthesis of 14 cited trials, updated Oct 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone
Oncology Meta-analysis
Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone New analysis suggests dual-target immune checkpoint inhibitors may improve survival for advanced gastric cancer patients
This network meta-analysis evaluated immune checkpoint inhibitor regimens versus chemotherapy for patients with advanced gastric cancer. The…
A large network meta-analysis suggests dual-target immune checkpoint inhibitors combined with chemotherapy may improve survival for advanced…
May 24, 2026
Review outlines immunotherapy roadmap for gastric cancer patients with noted limitations
Allergy & Immunology Sys. Review
Review outlines immunotherapy roadmap for gastric cancer patients with noted limitations New Immunotherapy Strategies May Help More Gastric Cancer Patients
This review examines immunotherapy options for patients with gastric cancer. The authors discuss various modalities including immune-checkpo…
New immunotherapy strategies could help more gastric cancer patients by turning cold tumors hot and personalizing treatment.
Frontiers May 12, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Allergy & Immunology Sys. Review
Review of combination strategies for digestive system tumors including gastric and colorectal cancer Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Frontiers Apr 23, 2026
Digital Nutritional Care Reduces Malnutrition and Weight Loss in Post-Gastrectomy Gastric Cancer Patients
Oncology Cohort
Digital Nutritional Care Reduces Malnutrition and Weight Loss in Post-Gastrectomy Gastric Cancer Patients Digital nutrition care helped patients recover faster after stomach cancer surgery
This retrospective controlled study of 150 patients after radical gastrectomy compared a structured digital nutritional care model against r…
A digital nutrition program helped patients recover faster after stomach cancer surgery, improving weight and malnutrition rates compared to…
Frontiers Apr 23, 2026
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
Oncology Phase II
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Apr 21, 2026
Probiotics shorten hospital stay and improve gut recovery after open gastrectomy for gastric cancer
Gastroenterology RCT
Probiotics shorten hospital stay and improve gut recovery after open gastrectomy for gastric cancer Probiotics may shorten hospital stay after gastric cancer surgery in small trial
In a single-centre randomized controlled trial of 42 patients undergoing open gastrectomy for gastric cancer, 10 days of postoperative probi…
Taking probiotics after open gastric cancer surgery may help patients leave the hospital sooner and recover their gut function faster.
Apr 19, 2026
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity
Oncology Phase II
Extensive intraoperative peritoneal lavage after gastrectomy for gastric cancer with peritoneal cytology positivity Can washing the belly during surgery help prevent stomach cancer from coming back?
This single-arm exploratory phase 2 trial in 13 patients with gastric cancer and positive peritoneal cytology evaluated extensive intraopera…
A thorough belly wash during stomach cancer surgery kept patients free from recurrence for 14.5 months if their fluid tests showed no cancer…
Apr 19, 2026
Electroacupuncture at ST36, ST37, and PC6 may shorten recovery times after laparoscopic gastrectomy for gastric cancer
Gastroenterology RCT
Electroacupuncture at ST36, ST37, and PC6 may shorten recovery times after laparoscopic gastrectomy for gastric cancer Electroacupuncture may speed recovery after gastric cancer surgery in a small study
In this randomized controlled trial of 60 patients who underwent laparoscopic radical gastrectomy for gastric cancer, electroacupuncture at …
Electroacupuncture helped gastric cancer surgery patients pass gas, move their bowels, and walk sooner while reducing pain after waking from…
Apr 17, 2026
Splenectomy versus spleen preservation during total gastrectomy for gastric cancer in adults
Oncology Sys. Review
Splenectomy versus spleen preservation during total gastrectomy for gastric cancer in adults Should your surgeon remove your spleen during stomach cancer surgery?
This systematic review of randomized controlled trials evaluated adults undergoing total gastrectomy for gastric cancer in Asia and South Am…
Removing the spleen during stomach cancer surgery may be unnecessary and increases infection risks, challenging a long-standing practice.
Cochrane Apr 12, 2026

Questions about Gastric Cancer

Does CIK/DC-CIK cell therapy improve survival rates for gastric cancer?

Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.

Full answer →
Does EGCG have therapeutic effects on digestive system diseases like gastric cancer?

Yes, EGCG shows therapeutic effects against gastric cancer in lab and animal studies by inhibiting cell growth, inducing apoptosis, and altering immune signals, but human trials are lacking.

Full answer →
Can machine learning predict anastomotic leaks in gastric cancer patients?

Yes, machine learning models can predict anastomotic leaks in gastric cancer patients with good accuracy, especially when using postoperative indicators and immunonutritional indices.

Full answer →
Does enteral immunonutrition reduce infection risks after gastric cancer surgery?

Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition, especially when given for 7–10 days perioperatively.

Full answer →